Regimens set to overtake monotherapies in total immuno-oncology (IO) sales

But what effect does this have on costs? IQVIA ran an analysis using IQVIA’s Oncology Link, Regimen Link, and Forecast Link modules to compare checkpoint inhibitor sales to those of the constituent oncology drugs within a regimen. Explore what was uncovered, in your free article.